JP2006512281A - 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 - Google Patents
乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 Download PDFInfo
- Publication number
- JP2006512281A JP2006512281A JP2003585716A JP2003585716A JP2006512281A JP 2006512281 A JP2006512281 A JP 2006512281A JP 2003585716 A JP2003585716 A JP 2003585716A JP 2003585716 A JP2003585716 A JP 2003585716A JP 2006512281 A JP2006512281 A JP 2006512281A
- Authority
- JP
- Japan
- Prior art keywords
- cyclopamine
- treatment
- skin
- medicament
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
その生物学的標的へのシクロパミンの結合に関与するシクロパミン分子の領域を含むが、それに加えて、新たに誘導される分子が引き続き同じ生物学的標的(すなわちスムーズンドタンパク質)に特異的に結合して本発明及び国際公開公報第02/078703号及び国際公開公報第02/078704号の中で開示されるシクロパミンの生物学的作用を及ぼすことができるような、親シクロパミン分子の修飾を含む分子。シクロパミンのそのような修飾は、生じる分子が安定であり、シクロパミンと同じ生物学的標的に特異的に結合して本発明及び国際公開公報第02/078703号及び国際公開公報第02/078704号の中で開示されるシクロパミンの生物学的作用を及ぼす能力を有することを条件として、シクロパミン分子内の分子基の1又はそれ以上の置換又は欠失又はシクロパミン分子への分子基(特に小分子基、例えばメチル基)の付加を含みうる。シクロパミンからのそのような新しい分子の誘導は当業者によって容易に実現することができ、また新たに誘導された分子におけるシクロパミンの生物学的作用の保持の継続又は廃止も、例えば本明細書及び国際公開公報第02/078703号及び国際公開公報第02/078704号の中で開示される生物学的作用に関して試験することにより、当業者によって容易に決定されうる。
Claims (13)
- 細胞分化障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又はシクロパミンの製薬上許容される塩の使用。
- 皮膚細胞の分化障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又はシクロパミンの製薬上許容される塩の使用。
- 乾癬を有する患者への治療適用のための薬剤を製造するための、シクロパミン又はシクロパミンの製薬上許容される塩の使用。
- プログラム細胞死の障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又はシクロパミンの製薬上許容される塩の使用。
- 皮膚細胞又はそれらに由来する腫瘍細胞のプログラム死の障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又はシクロパミンの製薬上許容される塩の使用。
- 乾癬を有する患者への治療適用のための、製薬上許容される担体中にシクロパミン及びコルチコステロイドを含有する製薬組成物。
- 上記シクロパミン濃度が10mM−20mMの範囲内であり、及び上記コルチコステロイドが0.5mg/g−1.0mg/gの濃度範囲内のクロベタゾール17−プロピオネート又は10mM−50mMの濃度範囲内のヒドロコルチゾンのいずれかであることを特徴とする、請求項6に記載の製薬組成物。
- 細胞分化障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又は明細書の中で述べられているシクロパミンの誘導体の使用。
- 皮膚細胞の分化障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又は明細書の中で述べられているシクロパミンの誘導体の使用。
- 乾癬を有する患者への治療適用のための薬剤を製造するための、シクロパミン又は明細書の中で述べられているシクロパミンの誘導体の使用。
- プログラム細胞死の障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又は明細書の中で述べられているシクロパミンの誘導体の使用。
- 皮膚細胞又はそれらに由来する腫瘍細胞のプログラム死の障害に関連する疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又は明細書の中で述べられているシクロパミンの誘導体の使用。
- 高い色素沈着に関連する母斑又は皮膚疾患を有する患者への治療適用のための薬剤を製造するための、シクロパミン又はシクロパミンの製薬上許容される塩の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2002/000017 WO2002078704A1 (en) | 2001-07-02 | 2002-04-19 | Use of cyclopamine in the treatment of psoriasis |
PCT/TR2003/000017 WO2003088964A1 (en) | 2002-04-19 | 2003-03-17 | Use of cyclopamine in the treatment of psoriasis and other skin disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010028010A Division JP5424923B2 (ja) | 2001-07-02 | 2010-02-10 | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006512281A true JP2006512281A (ja) | 2006-04-13 |
Family
ID=29247069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003585716A Pending JP2006512281A (ja) | 2002-04-19 | 2003-03-17 | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 |
Country Status (15)
Country | Link |
---|---|
US (6) | US7605167B2 (ja) |
EP (2) | EP1411938B1 (ja) |
JP (1) | JP2006512281A (ja) |
KR (4) | KR20070108287A (ja) |
CN (2) | CN1835748A (ja) |
AT (1) | ATE309802T1 (ja) |
AU (1) | AU2003230541B2 (ja) |
BR (1) | BR0309396A (ja) |
CA (3) | CA2452152A1 (ja) |
DE (1) | DE60302348T2 (ja) |
DK (1) | DK1496895T3 (ja) |
EA (1) | EA200401355A1 (ja) |
ES (1) | ES2253672T3 (ja) |
MX (1) | MXPA04010294A (ja) |
WO (1) | WO2003088964A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010132691A (ja) * | 2001-07-02 | 2010-06-17 | Tas Sinan | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 |
JP2011529102A (ja) * | 2008-07-28 | 2011-12-01 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Smoアンタゴニストとしての1,2,4−オキサジアゾール置換ピペリジン及びピペラジン誘導体 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
DE60028411T2 (de) | 1999-10-13 | 2007-01-04 | Johns Hopkins University School Of Medicine | Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20170326118A1 (en) * | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
CA2452152A1 (en) * | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
CN102241727B (zh) | 2004-08-27 | 2015-03-25 | 无限药品股份有限公司 | 环杷明类似物及其使用方法 |
WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
ES2547421T3 (es) | 2005-10-31 | 2015-10-06 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para diagnosticar y tratar el cáncer |
US20090156611A1 (en) * | 2005-11-11 | 2009-06-18 | Licentia Ltd. | Mammalian hedgehog signaling modulators |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
US20110034498A1 (en) * | 2006-03-24 | 2011-02-10 | Mcgovern Karen J | Dosing regimens for the treatment of cancer |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
AU2008223355B2 (en) | 2007-03-07 | 2014-03-20 | Infinity Discovery, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
CN101675054B (zh) | 2007-03-07 | 2014-05-14 | 无限发现股份有限公司 | 环杷明内酰胺类似物及其使用方法 |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
PE20091180A1 (es) * | 2007-12-27 | 2009-08-26 | Infinity Pharmaceuticals Inc | Tratamientos terapeuticos contra el cancer |
ES2610130T3 (es) | 2007-12-27 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Métodos para reducción estereoselectiva |
CN101990542A (zh) * | 2008-02-08 | 2011-03-23 | 德克萨斯大学董事会 | 环巴胺酒石酸盐及其用途 |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
WO2010080817A2 (en) * | 2009-01-06 | 2010-07-15 | Utah State University | Carbohydrate-cyclopamine conjugates as anticancer agents |
GB0900484D0 (en) | 2009-01-13 | 2009-02-11 | Angeletti P Ist Richerche Bio | Therapeutic agent |
WO2011017551A1 (en) | 2009-08-05 | 2011-02-10 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
GB0916608D0 (en) | 2009-09-22 | 2009-11-04 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2010314905A1 (en) * | 2009-11-06 | 2012-05-24 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
AU2011235904B2 (en) | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
WO2012037217A1 (en) | 2010-09-14 | 2012-03-22 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
AU2016271468B2 (en) | 2015-06-04 | 2020-01-02 | Sol-Gel Technologies Ltd. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物および使用方法 |
US11424772B2 (en) | 2018-12-06 | 2022-08-23 | Berex, Inc. | Receiver architectures with parametric circuits |
WO2022271702A1 (en) * | 2021-06-21 | 2022-12-29 | Palvella Therapeutics, Inc. | Methods and compositions for treating gorlin syndrome |
CN117940170A (zh) | 2021-09-13 | 2024-04-26 | 辛南·塔斯 | 有效干预人类衰老和衰老疾病及其效果 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000041545A2 (en) * | 1999-01-13 | 2000-07-20 | Ontogeny, Inc. | Regulators of the pct or smoothened pathway, compositions and uses related thereto |
WO2000074706A1 (en) * | 1999-06-08 | 2000-12-14 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
WO2001027135A2 (en) * | 1999-10-13 | 2001-04-19 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
JP2002511415A (ja) * | 1998-04-09 | 2002-04-16 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
EP1360958A2 (en) * | 2000-07-17 | 2003-11-12 | Centro de Investigation y Desarrollo de Medicamentos (CIDEM) | Liposomic formulation of clobetasol propionate |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH649923A5 (de) * | 1980-10-06 | 1985-06-28 | Glaxo Group Ltd | Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide. |
US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
WO1998035020A2 (en) | 1997-02-10 | 1998-08-13 | The Presidents And Fellows Of Harvard College | Methods for modulating hematopoiesis and vascular growth |
US7741298B2 (en) | 1997-06-20 | 2010-06-22 | New York University | Method and compositions for inhibiting tumorigenesis |
US6238876B1 (en) | 1997-06-20 | 2001-05-29 | New York University | Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma |
US20050130922A1 (en) | 1997-06-20 | 2005-06-16 | Altaba Ariel R.I. | Method and compositions for inhibiting tumorigenesis |
US6432970B2 (en) * | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US6867216B1 (en) * | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
US20050080138A1 (en) | 1999-09-16 | 2005-04-14 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1646395B8 (en) * | 1999-11-30 | 2014-12-17 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US6951839B1 (en) * | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US6683108B1 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Agonists of hedgehog signaling pathways and uses related thereto |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
JP4954426B2 (ja) | 2000-06-16 | 2012-06-13 | キュリス,インコーポレイテッド | 血管形成調節組成物及び利用 |
US20040060568A1 (en) | 2000-10-13 | 2004-04-01 | Henryk Dudek | Hedgehog antagonists, methods and uses related thereto |
US20020165221A1 (en) * | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
AU2002247847A1 (en) | 2001-04-09 | 2002-10-21 | Lorantis Limited | Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
DE60113733T2 (de) * | 2001-07-02 | 2006-06-29 | Tas, Sinan | Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren |
CA2452152A1 (en) * | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
RU2322984C2 (ru) * | 2001-10-05 | 2008-04-27 | Комбинаторкс, Инкорпорейтед | Комбинации для лечения иммуновоспалительных расстройств |
US6927205B2 (en) * | 2003-04-28 | 2005-08-09 | Procyte Corporation | Compositions and methods for treatment of psoriasis |
KR20050037103A (ko) | 2003-10-17 | 2005-04-21 | 주식회사 엘지생활건강 | 피부 미백용 화장료 조성물 |
CN102241727B (zh) * | 2004-08-27 | 2015-03-25 | 无限药品股份有限公司 | 环杷明类似物及其使用方法 |
ES2403006T3 (es) * | 2005-08-22 | 2013-05-13 | The Johns Hopkins University | Antagonistas de la vía Hedgehog para tratar enfermedades |
-
2002
- 2002-04-19 CA CA002452152A patent/CA2452152A1/en not_active Abandoned
- 2002-04-19 EP EP02736467A patent/EP1411938B1/en not_active Expired - Lifetime
-
2003
- 2003-03-17 CA CA2481499A patent/CA2481499C/en not_active Expired - Fee Related
- 2003-03-17 CA CA2636960A patent/CA2636960C/en not_active Expired - Fee Related
- 2003-03-17 KR KR1020077025034A patent/KR20070108287A/ko active Application Filing
- 2003-03-17 JP JP2003585716A patent/JP2006512281A/ja active Pending
- 2003-03-17 KR KR10-2004-7016679A patent/KR20040102117A/ko active Application Filing
- 2003-03-17 DK DK03723620T patent/DK1496895T3/da active
- 2003-03-17 BR BR0309396-4A patent/BR0309396A/pt not_active IP Right Cessation
- 2003-03-17 DE DE60302348T patent/DE60302348T2/de not_active Expired - Lifetime
- 2003-03-17 AU AU2003230541A patent/AU2003230541B2/en not_active Ceased
- 2003-03-17 EA EA200401355A patent/EA200401355A1/ru unknown
- 2003-03-17 MX MXPA04010294A patent/MXPA04010294A/es active IP Right Grant
- 2003-03-17 AT AT03723620T patent/ATE309802T1/de not_active IP Right Cessation
- 2003-03-17 WO PCT/TR2003/000017 patent/WO2003088964A1/en active IP Right Grant
- 2003-03-17 EP EP03723620A patent/EP1496895B1/en not_active Expired - Lifetime
- 2003-03-17 KR KR1020087024138A patent/KR20080096605A/ko not_active Application Discontinuation
- 2003-03-17 KR KR1020087024137A patent/KR20080094739A/ko active Search and Examination
- 2003-03-17 ES ES03723620T patent/ES2253672T3/es not_active Expired - Lifetime
- 2003-03-17 CN CNA038087847A patent/CN1835748A/zh active Pending
- 2003-03-17 CN CN200910146214A patent/CN101642458A/zh active Pending
- 2003-10-09 US US10/682,662 patent/US7605167B2/en not_active Expired - Fee Related
- 2003-10-09 US US10/682,584 patent/US7893078B2/en not_active Expired - Fee Related
-
2007
- 2007-10-18 US US11/874,653 patent/US7629352B2/en not_active Expired - Fee Related
- 2007-10-18 US US11/874,631 patent/US8025893B2/en not_active Expired - Fee Related
-
2009
- 2009-07-22 US US12/460,620 patent/US9757361B2/en not_active Expired - Fee Related
-
2011
- 2011-01-13 US US12/930,677 patent/US20110104254A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511415A (ja) * | 1998-04-09 | 2002-04-16 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
WO2000041545A2 (en) * | 1999-01-13 | 2000-07-20 | Ontogeny, Inc. | Regulators of the pct or smoothened pathway, compositions and uses related thereto |
WO2000074706A1 (en) * | 1999-06-08 | 2000-12-14 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
WO2001027135A2 (en) * | 1999-10-13 | 2001-04-19 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
EP1360958A2 (en) * | 2000-07-17 | 2003-11-12 | Centro de Investigation y Desarrollo de Medicamentos (CIDEM) | Liposomic formulation of clobetasol propionate |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010132691A (ja) * | 2001-07-02 | 2010-06-17 | Tas Sinan | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 |
JP2011529102A (ja) * | 2008-07-28 | 2011-12-01 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Smoアンタゴニストとしての1,2,4−オキサジアゾール置換ピペリジン及びピペラジン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5424923B2 (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
JP2006512281A (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
Wang et al. | Genistein suppresses psoriasis-related inflammation through a STAT3–NF-κB-dependent mechanism in keratinocytes | |
RU2533458C2 (ru) | Композиции, содежащие берберин или его аналоги для лечения кожных заболеваний, связанных с розацеа или с покраснением лица | |
US9446127B2 (en) | Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss | |
JP2000515523A (ja) | 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用 | |
Wang et al. | A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation | |
Zhu et al. | 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation | |
JP2008540327A (ja) | 核内受容体転写因子の分解を増強するための方法及び組成物並びにその使用 | |
CA3221964A1 (en) | Nitroxoline for use in the treatment of cutaneous neurofibroma | |
MX2008009442A (es) | Uso de la minosina o un derivado de la misma, en el tratamiento de las manifestaciones cutaneas de la psoriasis y de los desordenes cutaneos relacionados con esta y una composicion cosmetica o farmaceutica que la comprende. | |
JP2009143963A (ja) | 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ/スムーズンド信号を使用する腫瘍を治療するための製薬組成物 | |
US20180185391A1 (en) | Drug Treatment Of Psoriasis And Of Other Skin Disorders Associated With Inhibition Of Differentiation Of Epidermal Cells | |
US20120258937A1 (en) | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis | |
Phung et al. | Fibrous Proliferations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090811 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100215 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101001 |